Alnylam Pharmaceuticals, Inc.ALNYNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating

Buy

26 analysts·High coverage

85%

Rating Distribution

Strong Buy

00%

Buy

2285%

Hold

415%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 38% higher.

Bear Case

$351.00

-2%

Consensus

$494.07

+38%

Bull Case

$570.00

+59%

Price Range26 analysts

Low

Consensus

High

$351.00

$570.00

Current Target

Current Price

$359.26

Upside to Target

$134.81

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$7.94(14 analysts)

P/E1107x

Current: 1106.9x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+27.05%

EPS+77.60%

FY2028

Rev+20.30%

EPS+38.77%

FY2029

Rev+15.00%

EPS+26.38%

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+107.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 12, 2026Needham

Alnylam price target raised to $529 from $520 at Needham

Target:$529.00

+32.8%from $398.29

Jan 12, 2026Raymond James

Raymond James Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Target:$472.00

+18.5%from $398.29

Jan 8, 2026Truist Financial

Alnylam price target lowered to $530 from $535 at Truist

Target:$530.00

+26.5%from $419.07

Jan 6, 2026Bernstein

Alnylam price target lowered to $491 from $525 at Bernstein

Target:$491.00

+26.7%from $387.44

Dec 15, 2025Leerink Partners

Alnylam price target lowered to $351 from $370 at Leerink

Target:$351.00

-12.1%from $399.42

Dec 11, 2025Stifel Nicolaus

Alnylam price target raised to $508 from $495 at Stifel

Target:$508.00

+25.6%from $404.46

Nov 4, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Target:$570.00

+31.3%from $434.07

Oct 31, 2025Barclays

Alnylam price target raised to $527 from $460 at Barclays

Target:$527.00

+17.2%from $449.56

Oct 31, 2025Oppenheimer

Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at Oppenheimer

Target:$500.00

+11.2%from $449.56

Oct 31, 2025Chardan Capital

Alnylam price target raised to $475 from $400 at Chardan

Target:$475.00

+5.7%from $449.56

Oct 30, 2025UBS

Alnylam price target lowered to $549 from $550 at Jefferies

Target:$549.00

+22.1%from $449.56

Oct 30, 2025Morgan Stanley

Alnylam price target raised to $495 from $475 at Morgan Stanley

Target:$495.00

+10.1%from $449.56

Oct 22, 2025Cantor Fitzgerald

Alnylam price target raised to $450 from $325 at Cantor Fitzgerald

Target:$450.00

-5.1%from $474.00

Oct 17, 2025Truist Financial

Alnylam price target raised to $535 from $459 at Truist

Target:$535.00

+11.6%from $479.19

Oct 6, 2025Morgan Stanley

Alnylam price target raised to $475 from $405 at Morgan Stanley

Target:$475.00

+4.1%from $456.35

Oct 6, 2025Stifel Nicolaus

Alnylam price target raised to $495 from $441 at Stifel

Target:$495.00

+8.5%from $456.35

Sep 5, 2025BMO Capital

Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital

Target:$470.00

+3.8%from $452.81

Jul 29, 2025Raymond James

Alnylam assumed with an Outperform at Raymond James

Target:$370.00

+11.9%from $330.55

Jul 21, 2025Truist Financial

Truist Securities Starts Alnylam Pharmaceuticals (ALNY) at Buy

Target:$385.00

+18.6%from $324.49

Jun 24, 2025BMO Capital

Alnylam price target raised to $360 from $300 at BMO Capital

Target:$360.00

+10.8%from $325.00

Mar 21, 2025Scotiabank

Alnylam price target raised to $338 from $300 at Scotiabank

Target:$338.00

+19.3%from $283.34

Jan 7, 2025Bernstein

Alnylam price target lowered to $310 from $314 at Bernstein

Target:$310.00

+31.4%from $235.95

Oct 24, 2024Canaccord Genuity

Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Target:$336.00

+13.9%from $294.87

Oct 1, 2024Canaccord Genuity

Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Target:$366.00

+33.7%from $273.69

Sep 27, 2024Bank of America Securities

BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Target:$307.00

+11.7%from $274.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance